Oruka Therapeutics (NASDAQ:ORKA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Oruka Therapeutics (NASDAQ:ORKA) from a sell rating to a hold rating in a report published on Saturday.

Several other equities analysts have also commented on ORKA. UBS Group upped their price target on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. HC Wainwright reiterated a “buy” rating and issued a $120.00 price target on shares of Oruka Therapeutics in a report on Monday, August 3rd. Piper Sandler restated an “overweight” rating and set a $180.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. BTIG Research reaffirmed a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research report on Monday, July 13th. Finally, Weiss Ratings upgraded Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $134.30.

Oruka Therapeutics Price Performance

NASDAQ ORKA opened at $105.14 on Friday. Oruka Therapeutics has a 12 month low of $12.84 and a 12 month high of $105.31. The company has a 50-day moving average of $83.59 and a 200-day moving average of $60.75. The company has a market cap of $6.34 billion, a P/E ratio of -54.20 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, equities research analysts anticipate that Oruka Therapeutics will post -2.06 EPS for the current year.

Insider Buying and Selling at Oruka Therapeutics

In other Oruka Therapeutics news, Director Carl Dambkowski sold 105,000 shares of Oruka Therapeutics stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $58.97, for a total transaction of $6,191,850.00. Following the transaction, the director directly owned 73,743 shares of the company’s stock, valued at $4,348,624.71. The trade was a 58.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $69.28, for a total transaction of $550,568.16. Following the sale, the insider owned 32,718 shares of the company’s stock, valued at approximately $2,266,703.04. This represents a 19.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 188,406 shares of company stock worth $12,019,683. 23.49% of the stock is currently owned by corporate insiders.

Institutional Trading of Oruka Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada lifted its stake in shares of Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in Oruka Therapeutics in the fourth quarter valued at approximately $37,000. PNC Financial Services Group Inc. purchased a new stake in shares of Oruka Therapeutics during the third quarter valued at approximately $39,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Oruka Therapeutics during the fourth quarter valued at approximately $67,000. Finally, State of Wyoming acquired a new position in shares of Oruka Therapeutics during the second quarter worth $213,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.